Beam Therapeutics Inc. (BEAM)
NASDAQ (NGS) NASDAQ (NGS) Primary 
XMEX 
Beam Therapeutics: Pivoting From Platform To Execution Stage
Beam Therapeutics Inc. pivots from platform story to execution-driven thesis, with regulatory clarity accelerating BEAM-302 and Risto-cel in 2026. BEAM-302's "in vivo" gene editing for AATD achieved a potential FDA accelerated approval pathway, derisking the lead pipeline and providing a major 2026 catalyst. Risto-cel targets Sickle Cell Disease but faces a crowded ex vivo market; best-in-class data and BLA submission are expected by end of 2026.
BEAM Outlines Key Strategic & Pipeline Goals for 2026, Stock Rises
Beam Therapeutics jumps 22% after outlining 2026 pipeline goals, including accelerated approval plans for BEAM-302 and a potential risto-cel BLA filing.
Can BEAM's Gene Editing Pipeline Create Long-Term Value Amid Rivalry?
Beam Therapeutics advances base-editing pipeline with risto-cel studies and FDA designations, but no approved products and rising competition loom.
Beam Therapeutics: Strong Buy On BEAM-101 Progress And In Vivo LNP Shots On Goal
Beam Therapeutics Inc. remains a Strong Buy, supported by robust BEAM-101 phase 1/2 BEACON trial data in sickle cell disease. BEAM-101 consistently achieved >60% Hemoglobin F induction,
Why Is Beam Therapeutics (BEAM) Up 15.9% Since Last Earnings Report?
Beam Therapeutics (BEAM) reported earnings 30 days ago. What's next for the stock?
BEAM vs. NTLA: Which Gene Editing Stock Holds More Potential?
Beam's broad early-stage pipeline and recent study progress take center stage as investors weigh its potential against rival NTLA's prospects.
Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Lags Revenue Estimates
Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $1.1 per share versus the Zacks Consensus Estimate of a loss of $0.98. This compares to a loss of $1.17 per share a year ago.
Beam Therapeutics (BEAM) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Beam Therapeutics (BEAM) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Beam Therapeutics Inc. (BEAM) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Beam Therapeutics (BEAM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Beam Therapeutics Inc. (BEAM)'s Technical Outlook is Bright After Key Golden Cross
From a technical perspective, Beam Therapeutics Inc. (BEAM) is looking like an interesting pick, as it just reached a key level of support. BEAM's 50-day simple moving average crossed above its 200-day simple moving average, which is known as a "golden cross" in the trading world.
Wall Street Analysts Think Beam Therapeutics (BEAM) Could Surge 76.15%: Read This Before Placing a Bet
The mean of analysts' price targets for Beam Therapeutics (BEAM) points to a 76.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Beam Therapeutics Inc. (BEAM) Presents At Citi's Biopharma Back To School Conference Transcript
Beam Therapeutics Inc. (NASDAQ:BEAM ) Citi's Biopharma Back to School Conference September 3, 2025 4:00 PM EDT Company Participants John Evans - CEO & Director Conference Call Participants Samantha Semenkow - Citigroup Inc., Research Division Presentation Samantha Semenkow Vice President All right. Good afternoon.
